Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Kroll Bond Rating Agency (KBRA) has released its Third-Quarter 2021 U.S. Bank Compendium, providing insights into the U.S. banking sector's performance and outlook for 2022. The report reviews 3Q21 results for U.S. banks under KBRA ratings, focusing on key credit metrics and ratios. Additionally, it highlights the top 10 banks with the lowest cost deposits and analyzes changes in return on assets and nonperforming asset ratios. The compendium also includes a detailed supplement of 187 rated bank debt issues. Amalgamated Financial Corp. (NASDAQ: AMAL) holds a BBB rating with a Stable Outlook.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its gastroenterology business, Salix Pharmaceuticals, will present new data on rifaximin at The Liver Meeting™ 2021, taking place virtually from Nov. 12-15, 2021. Two abstracts will be available to registered attendees, highlighting studies on rifaximin's role in reducing hospitalization and mortality in patients with hepatic encephalopathy, as well as its use in emergency department services for cirrhosis patients. XIFAXAN® (rifaximin) is indicated for reducing hepatic encephalopathy recurrence and treating IBS-D.
Bausch Health Companies (NYSE/TSX: BHC) announced its participation in two significant investor conferences. The leadership team, including Joseph C. Papa and Sam Eldessouky, will present at the Credit Suisse 30th Annual Healthcare Conference on Nov. 10, 2021, at 10:30 a.m. ET, and at the Evercore ISI HealthCONx Conference on Dec. 1, 2021, at 1:00 p.m. ET. A live webcast will be available on the company’s Investor Relations page.
Bausch Health Companies reported third-quarter 2021 revenues of $2.111 billion, down 1% from $2.138 billion year-over-year. GAAP net income surged to $188 million, compared to $71 million in Q3 2020. The company plans to launch IPOs for Solta Medical in December 2021 or January 2022, followed by Bausch + Lomb about 30 days later. Bausch Health reaffirmed its full-year 2021 guidance with revenue expectations of $8.40 – $8.60 billion and Adjusted EBITDA between $3.35 – $3.50 billion.
Bausch Health Companies (NYSE/TSX: BHC) will present seven scientific posters and data from its ARMOR surveillance study at the American Academy of Optometry and American Academy of Ophthalmology meetings held in November 2021. Key presentations include analyses on the newly FDA-approved XIPERE™ for macular edema and the Bausch + Lomb INFUSE® Multifocal contact lenses. The company's commitment to educating eye care professionals through promotional events highlights its dedication to addressing patient needs.
Bausch Health has launched the Biotrue® Eye Care Recycling program, the first of its kind in the United States, allowing consumers to recycle eye drop single dose units, lens cases, and Biotrue® multi-dose bottles. This initiative, in collaboration with TerraCycle, aims to reduce environmental waste from these products. Participants can sign up for the program, collect eligible items, and mail them to TerraCycle for proper recycling. The program supports Bausch's ongoing commitment to sustainability in eye care packaging.
Bausch Health and its subsidiary Salix Pharmaceuticals released the Liver Health Annual Trends Report, highlighting critical gaps in chronic liver disease (CLD) care in the U.S. The report surveyed 100 healthcare providers, revealing that 38% are unaware of CLD management guidelines. An alarming 51% do not follow current American Association for the Study of Liver Diseases (AASLD) guidelines. CLD affects approximately 4.5 million Americans, with increasing cases of nonalcoholic fatty liver disease noted. The report emphasizes the urgent need for improved education and adherence to treatment standards.
Bausch Health Companies Inc. (BHC) announced the presentation of seven research findings related to its products XIFAXAN®, TRULANCE®, and RELISTOR® at the American College of Gastroenterology 2021 Annual Scientific Meeting in Las Vegas, from October 22-27, 2021. The new clinical data aims to improve patient care for gastrointestinal disorders. Salix Pharmaceuticals, a subsidiary, leads this initiative, reflecting its commitment to advancing gastrointestinal health.
XIPERE™, approved by the FDA, is the first medication for suprachoroidal injection in the U.S., targeting macular edema associated with uveitis. Developed by Bausch Health (BHC) and Clearside Biomedical (CLSD), it facilitates targeted delivery to the retina, potentially mitigating vision loss. Clinical trials indicate that 47% of patients showed significant visual acuity improvement compared to 16% in the control group. The product will be available in Q1 2022, offering a new therapeutic option in the eye health market.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has appointed Tom Vadaketh as Chief Financial Officer (CFO) of Bausch Pharma, effective January 3, 2022. Sam Eldessouky will transition to CFO of Bausch + Lomb following its IPO completion. Vadaketh brings over 30 years of financial experience from various roles, including CFO positions at reputable firms. This leadership change aims to strengthen Bausch Pharma's financial management as they prepare for the IPO of their eye health business. The company emphasizes its commitment to advancing global health through innovative products.